- Home
- PRLD vs VLT Comparison
PRLD vs VLT Comparison
Compare PRLD & VLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- VLT
- Stock Information
- Founded
- PRLD 2016
- VLT 1989
- Country
- PRLD United States
- VLT United States
- Employees
- PRLD N/A
- VLT N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- VLT Trusts Except Educational Religious and Charitable
- Sector
- PRLD Health Care
- VLT Finance
- Exchange
- PRLD Nasdaq
- VLT Nasdaq
- Market Cap
- PRLD 73.7M
- VLT N/A
- IPO Year
- PRLD 2020
- VLT N/A
- Fundamental
- Price
- PRLD $0.68
- VLT $9.85
- Analyst Decision
- PRLD Strong Buy
- VLT
- Analyst Count
- PRLD 2
- VLT 0
- Target Price
- PRLD $4.50
- VLT N/A
- AVG Volume (30 Days)
- PRLD 272.4K
- VLT 22.9K
- Earning Date
- PRLD 05-06-2025
- VLT 01-01-0001
- Dividend Yield
- PRLD N/A
- VLT 10.80%
- EPS Growth
- PRLD N/A
- VLT N/A
- EPS
- PRLD N/A
- VLT 0.64
- Revenue
- PRLD $7,000,000.00
- VLT N/A
- Revenue This Year
- PRLD N/A
- VLT N/A
- Revenue Next Year
- PRLD N/A
- VLT N/A
- P/E Ratio
- PRLD N/A
- VLT $16.69
- Revenue Growth
- PRLD N/A
- VLT N/A
- 52 Week Low
- PRLD $0.63
- VLT $9.29
- 52 Week High
- PRLD $6.80
- VLT $10.93
- Technical
- Relative Strength Index (RSI)
- PRLD 41.40
- VLT 11.38
- Support Level
- PRLD $0.71
- VLT $10.58
- Resistance Level
- PRLD $0.76
- VLT $10.67
- Average True Range (ATR)
- PRLD 0.07
- VLT 0.13
- MACD
- PRLD 0.01
- VLT -0.06
- Stochastic Oscillator
- PRLD 18.75
- VLT 4.94
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.